Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Palonosetron in Preventing Chemotherapy-Induced Nausea and V
2026-06-12
Ruhlmann and Herrstedt's review provides a comprehensive analysis of palonosetron hydrochloride, a next-generation 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV). The paper integrates pharmacologic and clinical trial evidence, highlighting palonosetron’s unique efficacy, especially in the delayed phase of CINV, and its implications for optimizing supportive care in oncology.
-
DeferoxamineB in Regulated Cell Death Assays: Novel Insights
2026-06-11
Discover how Deferoxamine (DeferoxamineB) expands the frontier of regulated cell death modeling in oncology. This in-depth article explores its mechanistic roles, assay optimization, and implications for anti-tumor immunity, offering a fresh perspective beyond standard iron chelation.
-
Gamithromycin: PK/PD Innovations and Translational Impact
2026-06-11
Explore the advanced pharmacokinetic and pharmacodynamic insights of Gamithromycin in veterinary research. This article uniquely bridges cutting-edge PK/PD findings with practical assay guidance, deepening your understanding of translational applications.
-
Propidium iodide (SKU B7758): Reproducible Cell Viability So
2026-06-10
This article delivers scenario-driven guidance for biomedical researchers using Propidium iodide (SKU B7758) in cell viability, apoptosis, and cell cycle assays. Drawing on practical laboratory challenges and the latest literature, it demonstrates how this DNA intercalating dye from APExBIO ensures reproducibility, sensitivity, and workflow compatibility.
-
ROS-Degradable Lipid Nanoparticles for Tumor-Selective mRNA
2026-06-10
The referenced study introduces a combinatorial library of biodegradable lipid nanoparticles engineered to leverage elevated ROS levels for tumor-selective mRNA delivery. This approach enables targeted gene expression in cancer cells, offering a versatile platform for mRNA therapeutics aimed at mutant RAS signaling.
-
IPA-3: Precision Inhibition of Pak1 for Targeted Neuroinflam
2026-06-09
Explore how IPA-3, a selective p21-activated kinase inhibitor, enables advanced research in Pak1 autophosphorylation inhibition, neuroinflammation, and cancer biology. This article offers a unique perspective on practical experimental design, integrating mechanistic depth and translational relevance.
-
Ferrostatin-1 (Fer-1): Precision Ferroptosis Inhibition in D
2026-06-09
Ferrostatin-1 (Fer-1) delivers nanomolar potency and selectivity for dissecting ferroptosis in cancer and neurodegenerative research. Learn how to optimize workflows, troubleshoot common pitfalls, and leverage recent photothermal therapy breakthroughs for robust, reproducible results.
-
2-Deoxy-D-glucose: Mechanistic Leverage for Translational Me
2026-06-08
Discover how 2-Deoxy-D-glucose (2-DG) is redefining glycolysis inhibition for translational research. Explore mechanistic insights, experimental best practices, and strategic guidance for oncology, immunology, and virology researchers. This article synthesizes emerging evidence, including immunometabolic regulation in T cells, and provides actionable workflow advice for leveraging APExBIO’s 2-DG in advanced experimental and combinatorial therapy design.
-
Acetylspiramycin (Spiramycin B): Mechanism and Resistance Be
2026-06-08
Acetylspiramycin (Spiramycin B) is a 16-membered macrolide antibiotic with potent activity against resistant Gram-positive and atypical pathogens. It inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit and demonstrates notably lower MICs compared to other macrolides in macrolide-resistant Mycoplasma pneumoniae. This dossier reviews its biological rationale, mechanism, evidence benchmarks, and application limits for resistance research.
-
Ribociclib Succinate (LEE011): Advanced CDK Inhibition in Ca
2026-06-07
Explore how Ribociclib succinate (LEE011 succinate), a leading CDK inhibitor, enables deeper mechanistic studies of cell cycle regulation and cancer therapeutics. This article delivers unique insights into protocol optimization and assay design, distinguishing itself from prior guides.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Application Guide
2026-06-06
The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody enables sensitive detection and signal amplification for rabbit IgG-based assays, such as immunofluorescence and immunohistochemistry. It is best suited for workflows requiring fluorescent secondary antibodies, but should not be used in diagnostic or therapeutic settings, nor with non-Cy3 detection channels.
-
Ibotenic Acid (SKU B6246): Reliable Tool for Neural Circuit
2026-06-05
This article explores how Ibotenic acid (SKU B6246) addresses key challenges in neuroscience research workflows, from cell viability to modeling neurodegenerative disorders. Drawing on validated protocols and literature—including DOI-linked evidence—this guide highlights practical optimization, data interpretation, and supplier selection, helping researchers achieve reproducible, high-quality results.
-
FGF4-FGFR1 Signaling Preserves Podocyte Survival in Diabetic
2026-06-05
The reference study uncovers a crucial protective role for podocyte-secreted FGF4 in diabetic kidney disease (DKD), demonstrating that FGF4-FGFR1 signaling maintains podocyte integrity and glomerular function. These findings highlight the pathway as a promising therapeutic target and offer new mechanistic insights into DKD progression.
-
Dabigatran etexilate: Direct Thrombin Inhibitor for Research
2026-06-04
Dabigatran etexilate is a potent, selective oral prodrug and direct thrombin inhibitor that provides predictable anticoagulant effects in preclinical and clinical research. Its rapid onset, high thrombin affinity, and oral bioavailability distinguish it from traditional anticoagulants. This article details its biological rationale, mechanism, and evidence benchmarks for advanced anticoagulation studies.
-
Revolutionizing Pyroptosis Research: Caspase-4 Assays in Tra
2026-06-04
This article provides translational researchers with a mechanistic, strategic, and practical framework for leveraging the Caspase-4 Colorimetric Assay Kit in the study of inflammasome biology and cell fate modulation. By bridging recent advances in organelle-targeted peptide therapeutics and inflammatory response biomarker detection, it positions robust colorimetric caspase assays as critical tools for moving discoveries from bench to bedside.